Repligen Corporation $RGEN Shares Acquired by Perceptive Advisors LLC

Perceptive Advisors LLC grew its stake in Repligen Corporation (NASDAQ:RGEN) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 315,541 shares of the biotechnology company’s stock after purchasing an additional 45,113 shares during the period. Perceptive Advisors LLC’s holdings in Repligen were worth $51,705,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Bayforest Capital Ltd acquired a new position in shares of Repligen in the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen in the 4th quarter valued at $33,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. HSBC lowered their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Stock Up 1.4%

RGEN stock opened at $133.55 on Thursday. The company has a fifty day moving average price of $121.10 and a 200 day moving average price of $136.86. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The company has a market cap of $7.53 billion, a price-to-earnings ratio of 148.39, a price-to-earnings-growth ratio of 2.54 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the prior year, the firm earned $0.39 EPS. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.